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Abstract 
Background: Accumulating evidence indicates that vascular endothelial growth factor 
(VEGF) and matrix metalloproteinase-9 (MMP-9) play a central role in the development of 
peritumoral brain edema (PTBE) associated with human brain tumors. However, the roles of 
these proteins, particularly of MMP-9, in PTBE associated with benign meningiomas have 
not been elucidated.  
Objective: We investigated the association between clinical features and biological factors, 
such as VEGF and MMP-9, and the incidence of PTBE and edema index (EI) in 60 patients 
with benign meningiomas.  
Methods: In this study, supratentorial lesions were examined for evaluating the extent of 
PTBE in the surrounding normal brain tissue. VEGF and MMP-9 expression was 
immunohistochemically examined. 
Results: Multivariate analysis revealed that the presence of pial blood supply (odds ratio, 
12.250; P = .0096) and VEGF (odds ratio, 7.683; P = .0155), but not MMP-9 (odds ratio 
1.178; P = .8113), expression are significant factors that independently predict the incidence 
of PTBE and influence EI. VEGF (P = .0397) and MMP-9 (P = .0057) expression correlates 
with the presence of pial blood supply. Moreover, tumors with high VEGF and MMP-9 
expression had higher EIs than those with high expression of either (P = .030).  
Conclusion: Our findings suggest indicate that MMP-9 expression was positively related to 
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VEGF expression and pial blood supply and promoted the occurrence of PTBE by inducing 
the disruption of the arachnoid membrane and formation of pial blood supply.  
 
Keywords: matrix metalloproteinase-9, meningioma, pial blood supply, peritumoral brain 
edema, vascular endothelial growth factor. 
 
Introduction 
Approximately 60% human meningiomas exhibit peritumoral brain edema (PTBE), 
which may be responsible for clinical symptoms such as headache and vomiting, and may be 
related to clinical outcome.1-3 To date, various possible causes of PTBE have been reported, 
which includes tumor size,1-3 location,1,4 histological differentiation,3-9   vascular density,10 
pial blood supply,2,3,10,11 tumor-related venous obstruction,12 sex hormone receptors,13,14 
vascular endothelial growth factor (VEGF) expression,10,11,15-18 and its receptor.19 Recently, 
matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in meningiomas has been well 
studied in relation to tumor invasiveness, PTBE, malignancy, and recurrence.20-23  
MMP-2 and MMP-9 are gelatinases that can degrade basement membrane-type 
collagen.24-26 At least 23 different MMPs are found in humans. These zinc-dependent 
endopeptidases degrade extracellular matrix components and are regulated on at least three 
levels: transcription, proteolytic activation of the zymogen, and inhibition of the active 
enzyme. Tissue inhibitors of metalloproteinases (TIMPs) are known to be the major 
endogenous regulators of MMPs in tissues.24-26 MMPs have been suggested to play an 
important role in tumor invasion and the metastasis of systemic cancers.27, 28 In brain tumors, 
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particularly in malignant gliomas, MMPs have been well studied.29-32 In recent studies, 
higher MMP-9 expression in meningiomas has been shown to correlate with tumor 
invasiveness.21 In PTBE associated with meningiomas, recent studies have shown that higher 
MMP-9 expression, but not MMP-2, correlates with PTBE.21,22  
 In recent studies, higher MMP-9 (33 von Randow AJ) or VEGF (reference 34) 
expression has been shown to correlate with PTBE in meningioma with higher pathological 
grades. However, limiting to benign pathologies, meningiomas differ in their degree of 
PTBE.33,34  
While the expression of biological factors such as VEGF and MMP-9 has been well studied 
in relation to pathological grades and PTBE associated with meningiomas, how these factors, 
particularly MMP-9, influence PTBE in benign meningioma or other significant factors for 
PTBE has not been well completely elucidated. Therefore, in the present study, we analyzed 
the association between clinical features and biological factors in supratentorial benign 
meningiomas using tissues that were surgically resected from 60 patients. 
 
Methods 
Patients and Specimens  
Meningioma samples (n = 60, from 60 patients) were obtained from Okayama 
University Hospital (Okayama, Japan). The tumors were from patients who underwent 
surgery between 1989 and 2004. Informed consent was obtained in all cases. All specimens 
were from primary tumors that were classified and graded according to the 2007 World 
Health Organization (WHO) classification criteria (reference 35).35 The location of tumors 
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was limited to the supuratentorial region and was categorized as convexity, falx, and 
parasagittal lesions for accurate estimation of the extent of edema and to ensure the 
uniformity of the surrounding tissues. 
Evaluation of Neuroradiological Imaging  
Before surgery, each patient’s tumor and any PTBE were assessed using magnetic 
resonance imaging (MRI). Tumor size was estimated from gadolinium-enhanced 
T1-weighted images. PTBE was evaluated on T2-weighted images. The tumor and PTBE 
were approximated from axial, coronal, and sagittal images as follows: the maximal 
perpendicular diameters (2a and 2b) of the tumor and PTBE were measured on axial scans, 
and the extent in the coronal direction (2c) was measured on coronal or sagittal scans. The 
total volume of the tumor and PTBE were then approximated using the formula for a 
spheroid (V = 4/3πabc). The relationship between the tumor and PTBE volume, i.e., edema 
index (EI) was defined as follows: EI = (Vedema + Vtumor)/Vtumor. The formula yields a value of 
1 when edema is absent. Pial-cortical arterial supply was identified by angiography in the 
anteroposterior and lateral views of the external and internal carotid arteries (vertebral artery) 
without prior knowledge of the MRI findings.  
  
Immunohistochemical Analysis  
Tumor sections (4.5 μm) were deparaffinized in xylene, rehydrated through graded 
alcohols, and immersed for 15 min in phosphate-buffered saline (PBS). For antigen retrieval, 
all sections were microwaved in 0.01 M citrate-buffered solution (pH 6.0) for 15 min. 
Endogenous peroxidase was inactivated by treatment with 3% hydrogen peroxide in 
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methanol for 15 min. The sections were incubated in normal horse serum for 15 min to block 
non-specific staining. A mouse monoclonal antibody against VEGF (BD PharMingen, San 
Diego, CA) or MMP-9 (Daiichi Fine Chemical, Toyama, Jpn) diluted to 1:100 in DAKO 
Antibody Diluent (DAKO, Carpinteria, CA) was applied. Incubations were performed in a 
humidity chamber at 4 °C overnight. As a negative control, mouse non-immune IgG was 
applied as the primary antibody. After three rinses with PBS, diluted biotinylated horse 
anti-mouse antibody (Vector Laboratories, Burlingame, CA) was applied for 30 min. 
Following three additional washes with PBS, avidin–biotin complex (Vector Laboratories) 
was applied for 30 min, followed by 0.06% diaminobenzidine (Sigma, St. Louis, MO) with 
0.01% hydrogen peroxide for 4 min. The sections were counterstained with hematoxylin. 
VEGF and MMP-9 expression was qualitatively scored as follows: 0 for no staining 
(nearly 0% of cells were labeled), 1+ for a trace of positive cells (less than 30% of cells were 
labeled), 2+ for moderately diffuse staining or sparsely intensive staining (30%–60% of cells 
were labeled, and less than 30% of cells were labeled with the strong intensity), and 3+ for 
strongly diffuse staining (60%–100% of cells were labeled).  
E.I. and S.O. classified the tumors according to 3 representative fields without prior 
knowledge of the patients’ clinical or radiological data. Staining of VEGF and MMP-9 was 
classified into two groups according to the scores. Lower 2 scores, 0 and 1+, were classified 
as the low-expression group and higher 2 scores, 2+ and 3+, were classified as the 
high-expression group.  
 
Statistical Analysis  
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Database management and statistical analysis were performed using the SAS 
software. Univariate and multivariate logistic analyses tested for edema using the following 
predictive variables: age, sex, pial blood supply, and VEGF and MMP-9 expression. The 
results were expressed as estimated coefficients, P values, and odds ratios (95% confidence 
intervals) for each variable. The tumor volume was analyzed by single linear regression 
analysis with EI as the dependent variable. The relationship between EI and clinical and 
biological variables, tumor volume, VEGF expression, and MMP-9 expression in relation to 
pial blood supply were evaluated by the Mann–Whitney U test. The relationship between 
VEGF expression and MMP-9 expression was evaluated using the Spearman rank 
correlation coefficient. The relationships between EI and histology, location, and the groups 
divided by the combination of VEGF expression and MMP-9 expression were evaluated by 
the Kruskal–Wallis test. P < .05 was considered statistically significant.  
 
Results 
Patient Characteristics 
Characteristics of the 60 patients included in this study are shown in Table 1. There 
were 16 males (26.7%) and 44 females (73.3%), with a mean age of 55.3 years (range, 22–81 
years). All tumors were classified according to the WHO criteria; 14 meningothelial, 11 
fibrous, 27 transitional, 2 psammomatous, 1 angiomatous, 3 microcystic, and 2 secretory 
meningiomas. The tumor locations were classified as supratentorial: 33 convexity, 16 
parasagittal, and 11 falx.  
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Immunohistochemical Staining 
The anti-human VEGF monoclonal antibody was immunoreactive, with evidence of 
cytoplasmic staining, in 48 cases (80%). Using our expression grading system, the tumor 
sections were classified as follows: 12 as 0, 27 as 1+, 16 as 2+, and 5 as 3+. The anti-human 
MMP-9 monoclonal antibody was immunoreactive, with evidence of cytoplasmic staining, 
in all cases. Using our grading system, the sections were classified as follows: 31 as 1+, 20 as 
2+, and 9 as 3+ (Figure 1) (Table 2).  
 
Univariate and Multivariate Logistic Regression Analyses 
To evaluate the factors influencing the incidence of PTBE, univariate and 
multivariate logistic regression analyses were performed (Table 3). The presence of pial 
blood supply and high VEGF expression were independent predictors of PTBE. Tumor 
volume showed a tendency toward predicting the incidence of PTBE in univariate analysis, 
but was not a statistically significant factor in multivariate analysis. Age, sex, and high 
MMP-9 expression were not statistically significant (P > .05) predictors for the incidence of 
PTBE.  
 
Correlation of Variables with Edema Index 
We evaluated the development of PTBE using EI (Figure 2). Tumor volume was not 
significantly correlated with EI (P = .1094). Pial blood supply was associated with a higher 
EI (EI = 6.720 ± 3.120 versus EI = 2.672 ± 0.837; P = .0012). EI was significantly higher in 
the high-VEGF group than in the low-VEGF group (EI = 5.148 ± 1.607 versus EI = 3.683 ± 
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1.834; P = .0007). The high-MMP-9 group showed a tendency toward a higher EI that was 
not significant (EI = 5.964 ± 2.532 versus EI = 2.542 ± 0.878; P = .062). As potential factors, 
histology and location were also evaluated. No significant difference in VEGF and MMP-9 
expression, pial blood supply, or EI was observed between histological subtypes (Table 4) 
(meningothelial meningiomas, EI = 6.142 ± 17.928; fibrous meningiomas, EI = 5.067 ± 
8.189; transitional meningiomas, EI = 2.666 ± 6.031; psammomatous meningiomas, EI = 
1.526 ± 0.744; angiomatous meningiomas, EI = 4.617; microcystic meningiomas, EI = 2.731 
± 2.922; secretory meningiomas, EI = 11.332 ± 6.172; P = .3062). No significant difference 
was observed between locations (convexity, EI = 5.469 ± 12.841; parasagittal, EI = 2.986 ± 
6.586; falx EI = 2.135 ± 2.164; P = .8349). Furthermore, location over the convexity was 
classified into frontal, parietal, temporal, and occipital, where the tumor mainly attached. 
Between these locations, there was no significant difference (frontal, EI = 3.977 ± 11.389; 
parietal, EI = 4.388 ± 7.498; temporal, EI = 3.560 ± 4.765; occipital, EI = 5.212 ± 11.079; P 
= .7446). 
 
Correlation of the Presence of Pial Blood Supply with Other Variables  
Because the presence of pial blood supply was identified as a clinical factor that 
independently predicts the incidence of PTBE and influences the development of PTBE, we 
analyzed the correlations between the presence of pial blood supply and other factors (Figure 
3). We observed that the presence of pial blood supply was significantly correlated with 
higher tumor volume (tumor volume = 38.014 ± 6.405 versus tumor volume = 16.756 ± 
2.932; P = .0008), high VEGF expression (VEGF score = 1.565 ± 0.207 versus VEGF score 
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= 1.027 ± 0.119; P = .0397), and high MMP-9 expression (MMP-9 score = 2.000 ± 0.178 
versus MMP-9 score = 1.405 ± 0.091; P = .0057).  We present a representative case showing 
high EI in the large convexity meningioma having high VEGF and MMP-9 expression 
(Figure 4). A large, homogeneously enhancing tumor on gadolinium-enhanced T1-weighted 
images (Figure 4A) was found in 52 year-old female patients. A remarkable PTBE was seen 
on T2-weighted images (Figure 4B). Partial tumor staining from meningeal arteries was 
shown by left internal carotid angiogram (Figure 4C) and external carotid angiogram (Figure 
4D). Pial blood supply from a branch of left anterior cerebral artery was also shown by left 
internal carotid angiogram (Figure 4C). Microscopic examination of hematoxylin and eosin 
staining revealed transitional  meningioma (Figure 4E). Immunohistochemical staining for 
VEGF (figure 4F) and MMP-9 (Figure 4G) were positive. VEGF and MMP-9 score were 3+ 
and 3+, respectively. 
 
Relationship between VEGF and MMP-9 
We analyzed the relationship between VEGF expression and MMP-9 expression 
(Figure 5). MMP-9 expression showed a positive relation with VEGF expression (P = .0479) 
(Figure 5A). Furthermore, tumors with high VEGF and MMP-9 expression showed a higher 
mean EI than those with low expression of either. Significant differences were observed 
between each group (P = .030) (Figure 5B).  
 
Discussion 
In this study, VEGF and MMP-9 expression varied in 60 benign supratentorial 
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meningiomas. Multivariate analysis revealed that the presence of pial blood supply and 
VEGF expression were significantly correlated with the incidence of PTBE and a higher EI. 
A trend towards correlation between MMP-9 and EI was found, although statistical 
significance was not reached. VEGF and MMP-9 expression was correlated with the 
presence of pial blood supply. Moreover, the probability of PTBE and a higher EI was greater 
in tumors with high VEGF and MMP-9 expression than in those with low expression of 
either. Although various possible causes of PTBE have been reported, such as tumor size, 
location, and histological subtypes, we could not detect other potential factors in this study. 
To address this, further studies with more samples of each group are needed.  
We found that pial blood supply and high VEGF expression were significant factors 
that independently predicted the incidence of PTBE and significantly correlated with EI 
consistent with several previous studies.2,3,10,11,16-18 However, these factors could play a 
different role in PTBE formation associated with meningiomas when combined.  Bitzer et al. 
and Sindou et al. showed a correlation between pial blood supply and tumor size.2, 3336 
Vascular enrichment has been reported as a potent factor for the development of PTBE.10,11,18 
Furthermore, Pitolesi et al. demonstrated that VEGF expression is related to MVD and pial 
blood supply.11  
We demonstrated that MMP-9 expression correlates with the presence of pial blood supply. 
In previous studies, MMP-9 expression was higher in non-benign meningomas than in 
benign meningiomas and correlated with severe edema, brain invasion, and tumor 
recurrence.20-23 Several studies have indicated that MMP-9 expression in benign 
meningiomas varies irrespective of the scoring method used.20-23,3437 Meningiomas are 
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located in the extra-axial space and separated from the brain parenchyma by the arachnoid 
membrane and pia mater. Since the mechanism of development of PTBE is vasogenic, 
breakdown of the blood–brain barrier or direct contact of the tumor with the brain 
parenchyma is essential for the development of PTBE.  The presence of pial blood supply 
reflects the disruption of the arachnoid membrane in the brain cortex that is formed of two 
layers of cells interrupted by a layer of basement membrane.2 There are several possible 
explanations for the relationship between pial blood supply and MMP-9 expression. First, 
MMP-9 expressed in meningiomas could play a role in the invasion of meningioma cells into 
the arachnoid membrane and its disruption for the development of PTBE. The correlation 
between MMP-9 expression and focal invasion of benign lesions has been previously 
demonstrated. Mizoue et al. reported that MMP-9 expression contributed to the infiltration of 
the dura mater by meningioma cells.3538 Nordqvist et al. analyzed the expression of MMP- 9 
in meningiomas associated with different degrees of brain invasion and edema. They 
demonstrated a relation between the extent of MMP-9 expression and arachnoid disruption 
and brain invasion.21 Second, MMP-9 could promote angiogenesis in brain parenchyma. The 
presence of pial blood supply could be the result of MMP-9-activated angiogenesis that is 
promoted by the invasion of the extracellular matrix by microvascular endothelial cells and 
the increased bio-availability of VEGF.36,3739,40 Barresi et al. found that a trend towards 
correlation between MMP-9 and VEGF expression in 50cases of meningiomas. 23 We 
showed a positive correlation between VEGF expression and MMP-9 expression in 
meningiomas. In some cases of our series, the presence of pial blood supply and high MMP-9 
expression with some degree of VEGF expression showed a high EI even in the small tumor. 
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On the other hand, in the larger tumor having low VEGF and MMP-9 expression, PTBE and 
pial blood supply were not observed. These findings imply that tumor having some degree of 
VEGF and MMP-9 expression may possess a high EI, regardless of tumor size. Moreover, 
the presence of pial blood supply, signifying the disruption of the arachnoid membrane, 
could be the visible result of high MMP-9 expression. These results were consistent with our 
statistical analyses.  
In conclusion, we analyzed VEGF and MMP-9 expression and significant factors 
which may contribute to PTBE in benign supratentorial meningiomas. Our findings suggest 
that MMP-9 expression was positively related to VEGF expression and pial blood supply and 
promoted the occurrence of PTBE by inducing the disruption of the arachnoid membrane and 
formation of pial blood supply.  
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Figure Legends 
Figure 1.  
Representative immunostainings of VEGF (upper column) and MMP-9 (lower column). 
Each microscopic pictures show negative (-), weakly positive (+), moderately positive (2+), 
and strongly positive (3+) immunostaining of each proteins (200 ×magnification). Scale bar 
= 100μm. 
 
Figure 2.  
The relationships between edema index (EI) and tumor volume (A), pial blood supply (B), 
VEGF expression (C), and MMP-9 expression (D). Both pial blood supply and high VEGF 
expression were significantly related to EI.  
 
Figure 3.  
The relationships between pial blood supply and tumor volume (A), VEGF score (B), and 
MMP-9 score (C). These factors significantly related to the existence of pial blood supply. 
 
Figure 4. 
A representative case of a meningioma having high tumor volume and marked edema. The 
gadolinium-enhanced T1-weighted image (A) and T2-weighted image (B) demonstrate a 
strong enhanced convexity meningioma with remarkable peritumoral brain edema. Lateral 
view of internal carotid (C) and external carotid (D) angiogram showed meningeal arterial 
supply to the center of convexity meningioma (arrow), and pial blood supply from anterior 
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cerebral artery to the rim of the tumor (arrowhead). Microscopic examination of hematoxylin 
and eosin staining revealed transitional meningioma (E). VEGF (F) and MMP-9 (G) 
expression was high in this tumor.  Scale bar = 100μm. 
 
Figure 5.  
The relationship between VEGF expression and MMP-9 expression (A) and the relationship 
between edema index (EI) and the groups divided by the combination of VEGF expression 
and MMP-9 expression (B). The significant correlation between VEGF expression and 
MMP-9 expression was found. Moreover, the coexpression of VEGF and MMP-9 was 
positively related to EI. 
  
 
 
Table 1   Clinical characteristics of 60 patients with meningioma 
 
 Distribution 
Age 
    Mean±SD 
 
55.3±13.7 
    Range 22-81 
Sex  
    Male 16 (26.7%) 
    Female 44 (73.3%) 
Location  
    Convexity 33 (55.0%) 
    Falx 11 (18.3%) 
    Parasagittal 16 (26.7%) 
Histology  
    Meningothelial 14 (23.3%) 
    Fibrous 11 (18.3%) 
    Transitional 27 (45.0%) 
    Psamommatous  2 (3.3%) 
    Angiomatous  1 (1.7%) 
    Microcystic  3 (5.0%) 
    Secretory  2 (3.3%) 
Tumor volume  
     Mean±SD 24.9±25.6 
     Range 1.1-128.9 
Edema volume  
     Mean±SD 26.2±41.8 
     Range 0-208.9 
Pial blood supply  
     Negative 37 (61.7%) 
     Positive 23 (38.3%) 
         Tumor and edema volume (cm3)  
 
 
 
Table 2   Summary of immunoreactivity for 60 samples of benign meningiomas 
 
 
                    Low expression               high expression 
      0      1+      2+     3+ 
VEGF     12     27     16     5 
MMP-9      0     31     20     9 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
Univariate and multivariate analysis of the factors causing peritumoral brain edema 
associated with meningiomas 
 
  Univariate   Multivariate  
Factors   ORa   95%CIb P   ORa   95%CIb P  
Age (10 years) 1.081 0.751-1.557 0.6759  1.304 0.802-2.121 0.2843
Sex (female) 0.789 0.244-2.556 0.6933  1.605 0.355-7.264 0.5387
Tumor volume 
(10cm3) 
1.291 0.989-1.685 0.0606  1.039 0.734-1.452 0.8228
Pial blood supplyc 9.778 2.461-38.855 0.0012 12.250 1.839-81.603 0.0096
VEGFd 7.765 1.960-30.757 0.0035  7.683 1.474-40.030 0.0155
MMP-9e 2.370 0.824-6.815 0.1092  1.178 0.307-4.526 0.8113
 
aOdds ratios.- b95% confidence interval.-cpositive vs. negative.-dHigh vs. low.- 
eHigh vs. low. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4    
 
. 
 Total 
n=60 
VEGF MMP-9 Pialbloodsupply 
   +/－ 
  EI 
Meningothelial 14   1.000±0.679 1.786±0.802 7/7 6.142±17.928
Fibrous   11   1.091±1.136 1.636±0.809 2/9 5.067±8.189 
Transitional 27   1.333±0.877 1.593±0.747 8/19 2.666±6.031 
Psamommatous 2   1.000±0.000 2.000±0.000 1/1 1.526±0.744 
Angiomatous 1   2.000 1.000 1/0 4.617 
Microcystic 3   1.333±1.155 1.333±0.577 3/0 2.731±2.922 
Secretory 2   2.000±0.000 1.500±0.707 1/1 11.332±6.172
P  0.5106 0.8165 0.1223 0.3062 
Mean values are expressed as mean ± SD. 
Kruskal–Wallis test was used. 
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